NeoPhore
NeoPhore is a Cambridge, UK-based pre-revenue biotech developing small-molecule drugs that target the DNA mismatch repair pathway for cancer immunotherapy, with a lead candidate targeted for 2025 and funding from a syndicate including Bristol Myers Squibb.
- Company typePrivate
- Founded2017
- HeadquartersCambridge, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What NeoPhore does
NeoPhore Limited is a UK-based, privately held immuno-oncology biotech founded in 2017 and headquartered in Cambridge. The company is developing small-molecule drugs that target the DNA mismatch repair (MMR) pathway as a mechanism to enhance cancer immunotherapy, positioning itself in the neoantigen immuno-oncology space via a small-molecule (rather than biologic or cell-therapy) modality. Its single core offering is a discovery-stage pipeline of MMR-pathway modulators, with a stated goal of delivering a lead clinical candidate by 2025; no product has reached clinical testing as of the source data.
The business model is pre-commercial: NeoPhore generates no revenue today and monetizes exclusively through equity financing and grant funding. It has raised approximately £31.1M (~$39.5M) in cumulative Series B funding (including a 2024 £9.6M / ~$12.2M extension) plus an Innovate UK grant, with Bristol Myers Squibb participating as a strategic pharma investor in the 2024 oversubscribed extension. Capital is deployed into medicinal-chemistry-led drug discovery with a lean 1-10 person organization.
The company operates with no distribution or commercial channels today, relying instead on scientific publications, investor relations, and conference participation for visibility. Its customer base upon commercialization will be oncology patients reached through future pharma partnerships or direct commercialization; no current pharma licensing, co-development, or royalty arrangements are disclosed.
NeoPhore firmographics
Firmographics- Name
- NeoPhore
- Legal name
- NeoPhore Limited
- Website
- https://neophore.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- NeoPhore is a Cambridge, UK-based pre-revenue biotech developing small-molecule drugs that target the DNA mismatch repair pathway for cancer immunotherapy, with a lead candidate targeted for 2025 and funding from a syndicate including Bristol Myers Squibb.
- Ownership category
- akta.pro rank
NeoPhore industry classification
Industry- Product category
- Oncology Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)
- akta.pro secondary industry
- Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)
Keywords
Where NeoPhore is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
NeoPhore business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Marketing channels1 record
NeoPhore product offering
Product offeringCore offering
NeoPhore is a pre-clinical stage immuno-oncology company developing small molecule drugs that target the DNA mismatch repair (MMR) pathway to stimulate the immune system against cancer. The company's drug discovery pipeline focuses on neoantigen-generating therapeutics intended to enhance cancer immunotherapy responses, with a lead drug candidate targeted to enter clinical testing by 2025.
Product overview
NeoPhore is a small molecule neoantigen immuno-oncology company developing a drug pipeline targeting the DNA mismatch repair (MMR) pathway for cancer immunotherapy. The company's single core offering is its small molecule drug discovery platform focused on MMR pathway modulation, with a lead drug candidate expected to enter clinical testing by 2025.
Differentiator
Problem solved
Functional benefit
Products and services
- Small Molecule MMR Pathway Drug Pipeline
Quantifiable outcome
- Lead drug candidate expected to enter clinical testing by 2025
Companies that use NeoPhore
Customer profileSegments1 record
Ideal customer profiles1 record
NeoPhore technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
NeoPhore partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Expansion highlights4 records
NeoPhore competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
NeoPhore social profiles
Digital presenceNeoPhore financial estimates
Financial estimateRevenue estimate
Valuation estimate
NeoPhore leadership team
Management profileNumber of profiles
Profiles3 records
NeoPhore funding detail
Funding detailFunding overview
Funding rounds6 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NeoPhore M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NeoPhore
What does NeoPhore do?
NeoPhore is a pre-clinical stage immuno-oncology company developing small molecule drugs that target the DNA mismatch repair (MMR) pathway to stimulate the immune system against cancer. The company's drug discovery pipeline focuses on neoantigen-generating therapeutics intended to enhance cancer immunotherapy responses, with a lead drug candidate targeted to enter clinical testing by 2025.
Is NeoPhore a public or private company?
NeoPhore is a private company. It is classified as venture growth investor backed and is currently operating.
When was NeoPhore founded?
NeoPhore was founded in 2017. It employs 1 to 10 people.
Where is NeoPhore based?
NeoPhore is headquartered in Cambridge, United Kingdom, in the Europe region.
Does NeoPhore have an API?
No public API is recorded for NeoPhore.
What industry is NeoPhore in?
NeoPhore's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAAANAK, Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies), with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 325414 and its SIC code is 2834.